

Jesse Schumaker

OF COUNSEL

Corporate
Boulder

jschumaker@wsgr.com
303-256-5909

FOCUS AREAS

Capital Markets
Corporate
Corporate Governance
Emerging Companies
Life Sciences
Mergers & Acquisitions

EXPERIENCE

Jesse Schumaker is Of Counsel in the Boulder, Colorado office of Wilson Sonsini Goodrich & Rosati, where he practices corporate law with a focus on the life sciences industry. He advises companies on general corporate matters, including formation and operation, corporate governance, early- and later-stage venture capital financings, debt financings, and public offerings. He also counsels companies on transactional matters, including mergers and acquisitions.

Prior to helping found our Boulder office, Jesse spent over seven years in our Palo Alto office, and before joining the firm, Jesse was in-house counsel for a Fortune 500 life sciences company in the San Francisco Bay Area.

CREDENTIALS

Education

- J.D., New York University School of Law
- B.A., Political Science, University of California, Berkeley

Admissions

- State Bar of California
- State Bar of Colorado
- State Bar of New York

MATTERS

Select Recent Transactions

- Soleno Therapeutics in its \$129 million public offering and concurrent private placement (2023)
- Thorne HealthTech in its \$680 million acquisition by L. Catterton (2023)
- Telesis Bio in its \$28 million private placement (2023)
- SetPoint Medical in its \$80 million preferred stock offering (2023)
- Minerva Surgical in its \$30 million private placement (2023)
- Soleno Therapeutics in its \$60 million private placement (2022)
- Earlens in its Series AA offering (2022)
- Enable Injections in its Series C offering (2022)
- Minerva Surgical in its initial public offering (2021)
- Thorne HealthTech in its initial public offering (2021)
- Codex DNA in its initial public offering (2021)
- Seer in its initial public offering (2020) and follow-on public offering (2021)
- Establishment Labs in its initial public offering (2018) and follow-on public offering (2020)
- iRhythm Technologies in its initial public offering (2016) and follow-on public offerings (2019, 2020)
- Allay Therapeutics in its Series C offering (2021)

- Circle Pharma in its Series C offering (2021)
- Setpoint Medical in its Series B' offering (2021)
- Aerin Medical in its Series D offering (2020)
- Element Science in its Series C offering (2020)